Endo International (Endo International) EBIT per Share

: $-10.16 (TTM As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

Endo International's EBIT per Share for the three months ended in Dec. 2023 was $-10.25. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-10.16.

During the past 12 months, the average EBIT per Share Growth Rate of Endo International was 18.70% per year. During the past 3 years, the average EBIT per Share Growth Rate was -15.80% per year. During the past 5 years, the average EBIT per Share Growth Rate was -8.50% per year. During the past 10 years, the average EBIT per Share Growth Rate was -4.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Endo International's EBIT per Share or its related term are showing as below:

ENDPQ' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -29.9 Med: 10.8 Max: 44.8
Current: -15.8

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Endo International was 44.80% per year. The lowest was -29.90% per year. And the median was 10.80% per year.

ENDPQ's 3-Year EBIT Growth Rate is ranked worse than
79.27% of 854 companies
in the Drug Manufacturers industry
Industry Median: 7.75 vs ENDPQ: -15.80

Endo International's EBIT for the three months ended in Dec. 2023 was $-2,412 Mil.

Endo International EBIT per Share Historical Data

The historical data trend for Endo International's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Endo International Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

0.86

2.17

0.07

-10.81

-10.17

Endo International Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT per Share	Get a 7-Day Free Trial															-1.02	0.01	0.15	-0.07	-10.25

Endo International EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Endo International's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-2390.933	/	235.219
=	-10.16

Endo International's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-2412.016	/	235.219
=	-10.25

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.16

Endo International (OTCPK:ENDPQ) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Endo International EBIT per Share Related Terms

Thank you for viewing the detailed overview of Endo International's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Endo International (Endo International) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Endo International PLC (OTCPK:ENDPQ) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

EO7:Germany

Address

Simmonscourt Road, Ballsbridge, First Floor, Minerva House, Dublin, IRL, 4

Website

https://www.endo.com

Endo International PLC is a specialty pharmaceutical company with a considerable presence in pain management, urology, orthopedics, endocrinology, bariatrics, and others. It operates in four segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. The company generates maximum revenue from the Branded Pharmaceuticals segment. Some of its products include XIAFLEX, SUPPRELIN, PERCOCET, TESTOPEL, VASOSTRICT, ADRENALIN, and APLISOL.

Executives

James Patrick Tursi	officer: Executive VP, Global R&D	106 ASHLEY COURT, MOORESTOWN NJ 08057
Frank B. Raciti	officer: VP, Controller and CAO	C/O ENDO HEALTH SOLUTIONS INC., 1400 ATWATER DRIVE, MALVERN PA 19355
Shane Cooke	director	TREASURY BUILDING LOWER GRAND CANAL ST., DUBLIN 2 L2 00000
William P Montague	director
Jennifer M Chao	director	7 PURITAN WOODS ROAD, RYE NY 10580
George Apostol	officer: EVP, Head of Global R&D	C/O ENDO INTERNATIONAL PLC, FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD, BALLSBRIDGE, DUBLIN 4 L2 00000
Mary Christine Smith	director	3658 50TH AVE NE, SEATTLE WA 98105
Mark T. Bradley	officer: EVP, Chief Financial Officer	C/O ENDO INTERNATIONAL PLC, FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD, BALLSBRIDGE, DUBLIN L2 00000
Mark G Barberio	director	19 WIK STREET, WILLIAMSVILLE NY 14221
Jack D. Boyle	officer: SVP, Interim Controller	C/O ENDO INTERNATIONAL PLC, FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD, BALLSBRIDGE, DUBLIN L2 00000
Roger H Kimmel	director	LATHAM & WATKINS, 885 THIRD AVENUE, NEW YORK NY 10022
Domenico Ciarico	officer: EVP & Chief Commercial Officer	C/O ENDO INTERNATIONAL PLC, FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD, BALLSBRIDGE, DUBLIN L2 00000
Rahul Garella	officer: EVP, Intl Pharmaceuticals	C/O ENDO INTERNATIONAL PLC, FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD, BALLSBRIDGE, DUBLIN L2 00000
Nancy J Hutson	director	64 MONTAUK AVENUE, STONINGTON CT 06378
Carrie Ann Nichol	officer: VP, Controller & CAO	927 GRANDVIEW DRIVE, EXTON PA 19341